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Abstract
Artificial intelligence (AI) has made impressive progress over the past few years, including many applications in medical
imaging. Numerous commercial solutions based on AI techniques are now available for sale, forcing radiology practices to learn
how to properly assess these tools. While several guidelines describing good practices for conducting and reporting AI-based
research in medicine and radiology have been published, fewer efforts have focused on recommendations addressing the key
questions to consider when critically assessing AI solutions before purchase. Commercial AI solutions are typically complicated
software products, for the evaluation of which many factors are to be considered. In this work, authors from academia and
industry have joined efforts to propose a practical framework that will help stakeholders evaluate commercial AI solutions in
radiology (the ECLAIR guidelines) and reach an informed decision. Topics to consider in the evaluation include the relevance of
the solution from the point of view of each stakeholder, issues regarding performance and validation, usability and integration,
regulatory and legal aspects, and financial and support services.
Key Points
• Numerous commercial solutions based on artificial intelligence techniques are now available for sale, and radiology practices
have to learn how to properly assess these tools.
•We propose a framework focusing on practical points to consider when assessing an AI solution in medical imaging, allowing
all stakeholders to conduct relevant discussions with manufacturers and reach an informed decision as to whether to purchase
an AI commercial solution for imaging applications.
• Topics to consider in the evaluation include the relevance of the solution from the point of view of each stakeholder, issues
regarding performance and validation, usability and integration, regulatory and legal aspects, and financial and support
services.
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Introduction
Artificial intelligence (AI) has made impressive progress
over the past few years, fueled in large part by advances in
its subfield of deep learning (DL). DL, itself part of ma-
chine learning (ML), is the main focus of these guidelines
and corresponds to a class of algorithms that learn directly
from data to produce the desired output, and has posted
human-level (or superhuman) performance in tasks such
as image recognition. This enthusiasm has spilled over into
medical imaging, and radiology departments are increas-
ingly receptive to such techniques, which promise to help
cope with ever-expanding workloads and ultimately im-
prove patients’ outcome. To help radiologists and other
physicians find their way in this new world, several guide-
lines describing good practices for conducting and
reporting AI-based research in medicine and radiology
have been published [1–6].
This rapid academic progress has been paralleled by
unprecedented investment and activity in private and pub-
lic companies, with numerous commercial solutions based
on AI techniques now available for sale. Medical device
regulation has also evolved, in particular with the notion
of AI-based software as a medical device (SaMD) [7].
Evaluation of AI offerings must include technical and
financial considerations, quality and safety factors, and
input from key stakeholders [8, 9]. Thus, our main goal
is to bring together authors from academia and industry in
order to provide a guide that will help radiologists select
the most appropriate commercial AI solution for their
needs, through a set of questions to challenge solution
providers when evaluating commercial AI solutions in
radiology (the ECLAIR guidelines). These are summa-
rized in Table 1, and Table 2 highlights the top 10 ques-
tions to consider. In the remainder of this paper, we will
assume that the reader has a basic knowledge of AI and
AI-related terminology, which can be found in other pub-
lications aiming at introducing AI to radiologists [10–13].
We also provide a glossary as supplementary material for
reference.
Relevance
What problem is the application intended to solve,
and who is the application designed for?
In assessing the relevance of the AI solution to one’s practice,
the fundamental questions to answer are what specific prob-
lem it is supposed to solve (the intended use), and under what
conditions (the indications of use)? There should be a clear
specific clinical indication (the use case) that the vendor
should be able to explain.
Basic points to consider include:
& What are the medical conditions to be diagnosed, treated,
and/or monitored?
& Who are the intended end-users—i.e., radiologists, clini-
cians, surgeons—as well as their required qualifications
and training?
& What are the principles of operation of the device and its
mode of action?
& Is the application intended to be used as a research tool or
for clinical use?
& Will the AI solution be used as a double reader, to triage
examinations, to perform quality control, or for some oth-
er function [10]?
& Does the system produce a diagnosis, a prognosis, or
quantitative data (lesion segmentation, organ volumes,
etc.)? [14, 15]
& Does the application provide useful information that was
not available before?
& Are there any other considerations such as patient selec-
tion criteria, indications, contra-indications, warnings?
For SaMD, the “intended use statement” of the product
regulatory documentation should provide this information.
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What are the potential benefits, and for whom?
Benefits can be assessed from the perspective of patients, radi-
ologists, referring physicians, hospitals, insurance companies,
the healthcare system, or society as a whole. Each view has its
own outcome measures, some of which are reported below.
Ideally, benefits should be linked to evidence, including scien-
tific publications and healthcare economics analyses.
Patients
AI software may increase the value of imaging in pa-
tient care in many ways [16]. Outcome measures to
assess the impact on patient management, such as diag-
nostic performance, diagnostic impact, therapeutic im-
pact, and quality of life, are detailed in dedicated pub-
lications [17].
Table 1 Checklist of points to consider when assessing a commercial AI solution in radiology
1. Relevance 1.1. What problem is the application intended to solve, and who is the application designed for?
Define the scope of application; end-users; research vs. clinical use; usage as double reader, triage, other; outputs
(diagnosis, prognosis, quantitative data, other), indications and contra-indications
1.2 .What are the potential benefits, and for whom?
Consider benefits for patients, radiologists/referring clinicians, institution, society
1.3. What are the risks associated with the use of the AI system?
Consider risks of misdiagnosis (including legal costs), of negative impact on workflow, of negative impact on quality of
training
2. Performance and validation 2.1. Are the algorithm’s design specifications clear?
Check robustness to variability of acquisition parameters; identify features (radiomics) or network architecture (deep
learning) used
2.2. How was the algorithm trained?
Assess population characteristics and acquisition techniques used, labeling process, confounding factors, and operating
point selection
2.3. How has performance been evaluated?
Check proper partitioning of training/validation/testing data, representativeness and open availability of data. Assess
human benchmarks, application scope during evaluation, source of clinical validation
2.4. Have the developers identified and accounted for potential sources of bias in their algorithm?
Assess training data collection, bias evaluation, stratification analyses
2.5. Is the algorithm fixed or adapting as new data comes in?
Check whether user feedback is incorporated, if regulatory approval is maintained, and if results are comparable with
previous versions. *
3. Usability and integration 3.1. How can the application be integrated into your clinical workflow?
Consider integration with your information technology (IT) platform, check for compliance with ISO usability standards,
consider issues related to practical management of the software
3.2. How exactly does the application impact the workflow?
Identify modifications to bring to your current workflow, identify roles in the new workflow (physicians and non-physicians)
3.3. What are the requirements in terms of information technology (IT) infrastructure?
Consider on-premise vs. cloud solutions. Identify requirements in terms of hardware and network performance, consider
network security issues
3.4. Interoperability - How can the data be exported for research and other purposes?
Check whether the export formats are suitable
3.5. Will the data be accessible to non-radiologists (referring physicians, patients)?
Check whether the form of the output is suitable for communication with patients/referring physicians
3.6. Are the AI model’s results interpretable?
Check whether and which interpretability tools (i.e. visualization) are used
4. Regulatory and legal aspects 4.1. Does the AI application comply with the local medical device regulations?
Check whether the manufacturer obtained regulatory approval from the country where the application will be used (CE,
FDA, UKCA, MDSAP, or other local guidance), and for which risk class
4.2. Does the AI application comply with the data protection regulations?
Check whether the manufacturer complies with local data protection regulations and provides contractual clauses
protecting patient’s data
5. Financial and support services
considerations
5.1. What is the licensing model?
Assess one-time fee vs. subscription models, total costs, scalability
5.2. How are user training and follow-up handled?
Check whether training sessions are included and at which conditions further training can be obtained
5.3. How is the maintenance of the product ensured?
Check whether regular maintenance is included, assess the procedure during downtime and for repair
5.4. How will potential malfunctions or erroneous results be handled?
Assess the procedure in the event of malfunction and post market surveillance and follow-up
* Note that at the time of writing of these guidelines, no adaptative AI application exists on the market.
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Radiologists and referring physicians
Some of the benefits and outcome measures to consider from
the perspective of radiologists and clinicians include:
& Increased productivity and decreased reporting time,
which can impact clinician’s and radiologist’s satisfaction
[18]
& Increased time spent with patients, which can impact pa-
tient’s and radiologist’s satisfaction [19]
& Reduced time spent on “menial” tasks
& Faster diagnosis in time-sensitive situations (e.g., stroke)
& Potential decrease in physical or psychological strain
& Increased quality control, reduced malpractice risk, legal
and insurance costs
Institution
Potential benefits for the institution include improved physi-
cian efficiency, more effective resource utilization, more rapid
care processes, and reduced malpractice risk. Formal health
economics assessments, such as cost-benefit and cost-
effectiveness analyses, are scarce and should be encouraged.
Solution vendors could be a good source of return on invest-
ment (RoI) analyses; although they are likely to be optimistic,
they should at least provide suitable RoI metrics that can be
recorded and confronted with reality as the system is de-
ployed. Different health care systems will require different
health economic modeling to ensure local RoI viability.
Society
Potential societal benefits include decreased healthcare costs,
increased access to healthcare with decreased variability in the
quality of care, and, ultimately, increased life expectancy and
quality of life.
What are the risks associated with the use of the AI
system?
All the benefits above come with related risks. In general, the
buyer should ask to review the risk assessment matrix and
risk-benefit analysis in the regulatory technical file provided
by the vendor, which covers some of these risks.
Risks related to the use of AI solutions, such as misdiag-
nosis, generate legal exposure. In this regard, the risks for the
buyer’s institution should be identified, and responsibilities
clearly assigned.
Other risks must be considered. The radiologist’s workflow
could be impacted negatively in case of poor integration (see
section “Usability and integration”) or poor reliability of the
AI system. Furthermore, although the training of radiologists
might be improved by an always-available double reader, AI
could have a negative impact by causing trainees to rely too
much on it, or more importantly, to neglect basic knowledge
of imaging signs.
Performance and validation
As for any diagnostic solutions, AI algorithms need to be
assessed following the standards for unbiased assessment in
a clinical context (e.g., STARD, TRIPOD, CHARMS), and
diagnostic performance measures must be available [3, 20,
21]. Nevertheless, AI-based products have specific features
that require particular guidance (e.g., TRIPOD-ML,
CONSORT-AI, SPIRIT-AI, and CLAIM guidelines) [1–6].
Are the algorithm’s design specifications clear?
Small details can have cascading effects on the performance
of AI algorithms [22, 23]. Thus, AI software vendors need to
disclose many details about how their software operates in
order to explain how real-world clinical imaging data can be
accommodated. Typically, a design specification should be
included in the technical file. In particular, vendors should
explain:
& Which image processing steps are used? How are differ-
ences in resolution, contrast, and intensity handled on im-
ages from different machines?
& For radiomics approaches, which features does the algo-
rithm assess? How does the algorithm represent images
prior to learning and analysis? This information can then
be linked back to peer-reviewed literature for critical ap-
praisal of performance.
Table 2 Top 10 questions to consider
1. What problem is the application intended to solve, and who is the
application designed for?
2. What are the potential benefits and risks, and for whom?
3. Has the algorithm been rigorously and independently validated?
4. How can the application be integrated into your clinical workflow and
is the solution interoperable with your existing software?
5. What are the IT infrastructure requirements?
6. Does the application conform to the medical device and the personal
data protection regulations of the target country, and what class of
regulation does it conform to?
7. Have return on investment (RoI) analyses been performed?
8. How is the maintenance of the product ensured?
9. How are user training and follow-up handled?
10. How will potential malfunctions or erroneous results be handled?
Eur Radiol
& For deep learning AI algorithms, which neural network is
used (e.g., U-Net is a popular architecture for segmenta-
tion)? Such information, ideally with reference to the rel-
evant literature, may help identify possible failure modes
of the algorithm. Vendors should be able and willing to
explain broadly how their algorithms operate to both non-
specialists and specialists embedded within radiology de-
partments. If not, this should count as a negative point in
the competitive analysis with other solutions.
How was the algorithm trained?
AI algorithms include many parameters, which must be
learned or “trained” from data (medical images) and la-
bels—annotations, which can be as broad as a diagnosis at-
tached to a whole image, or as specific as labeling particular
voxels with tags such as “lesion” or “necrosis.” They are then
validated on separate data (possibly multiple times) and final-
ly should be tested on external data, from another cohort or
machine. This last point is particularly important as it guards
against overfitting. Thus, ultimate performance depends criti-
cally on the data used. In general, one may refer to detailed
guidelines [3, 21, 24], but several points are of particular
importance:
& What data was used to train the AI algorithm? This must
include the number of patients, controls, images, and oc-
currence of pathology or abnormality. Clinical and demo-
graphic data on patients (with inclusion and exclusion
criteria) must be provided, together with information
about location and type of acquisition sites. Technical pa-
rameters including vendors, modalities, spatial and tem-
poral resolution of images, acquisition sequence details,
field strength if applicable, patient position, injection of
contrast agents, and the like must be specified. The sample
used to develop the algorithms should have characteristics
that are representative of the target population for which
the algorithm will be used to avoid bias (i.e., same age,
ethnicity, breast typology….), but also follow the same
processing steps that will be applied during deployment
[25].
& How was labeling performed? What was the experience
level of readers? How many readers per case? Were the
readers given realistic conditions for image interpretation?
In particular, did they have access to native resolution
images, with their usual viewers and tools? Did they have
access to relevant clinical information and other images?
Was there a time constraint?
& Are there confounding factors in the data? For example, in
multi-site data, were more patients at one site diagnosed
with a particular disease than in another site?
& Based on which criteria were the operating points chosen,
and on which dataset?
How has performance been evaluated?
First, for proper evaluation of generalizability, all algorithms
should be developed and evaluated on disjoint subsets of the
dataset. This essentially means that the algorithm should not
be tested on the same data on which it was developed. The
TRIPOD guidelines show different approaches to achieve
this. Some questions are common to all types of algorithms:
& What data was used to validate and tune the AI algorithm?
Is there an overlap with the training data? If so, this is a red
flag.
& What data was used to test the AI algorithm? Is there an
overlap with the training and validation data? Again, this
is a red flag.
& Is the test set realistic? Is it representative of the population
in which the system will be used (e.g., age, sex, BMI,
prevalence of pathologies, comorbidities)? If not, radiolo-
gists should be aware that results could be sub-optimal in
some cases that have not been thoroughly tested, such as
obese patients.
& Are the test set (including imaging and clinical data), and
the ground truth available and/or open for reproducibility?
& Has the algorithm been benchmarked against experts in
the field?
& Are performance results reported for the AI algorithm as a
stand-alone clinical decision support system, or as a sec-
ond reader? Has the added value for human readers (in
terms of performance) been assessed?
& Is the clinical validation done by sources external/
independent from the creator of the algorithm? Is the clin-
ical study design of good quality?
For practical use, it is particularly important to gauge
how robust the algorithm is to technical variations in the
images. The main points to assess are repeatability (same
machine, same time (e.g., back-to-back acquisitions) and
reproducibility (different machine, different sequence or
contrast, or different time). These should be covered in
the technical file. In particular, questions to consider
include:
& How reproducible is the algorithm against variability in
acquisition parameters (e.g. contrast, signal-to-noise, res-
olution parameters)? This is typically a weak point in
academic/research systems, where AI algorithms can eas-
ily latch onto acquisition details unrelated to pathology if
these are confounders, but commercial systems should
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present evidence that they are reproducible in the deploy-
ment environment [26].
& How repeatable (deterministic) is the algorithm? For algo-
rithms outputting single values (e.g., volumetry), the re-
peatability coefficient and Bland-Altman plots should be
provided.
& How does the algorithm handle differences in data quali-
ty? Was the algorithm evaluated on artefactual/non-ideal
data? What were the results?
The performance metrics to be used depend on the type of
algorithm and are detailed in existing guidelines [20, 21]:
& For classification algorithms (e.g., diagnosis): Are both
threshold-dependent (e.g., sensitivity, specificity) and
threshold-independent metrics (such as the area under
the receiver operating curve (ROC)) reported? For imbal-
anced datasets, are appropriate metrics (balanced accura-
cy, no-information rate, Kappa…) provided? Are confi-
dence intervals provided?
& For regression algorithms (e.g., linking clinical scores or
liquid biomarker levels to images, such as bone age as-
sessment): Are both metrics of typical performance (mean
average error (MAE)) and more extreme performance
(root mean-squared error (RMSE)) provided? For fore-
casting (prognosis), is a benchmark with respect to the
one-step naïve forecast, e.g., using mean absolute scaled
error [27] (MASE), provided?
& For detection algorithms (e.g., anomaly detection in mam-
mography): Are metrics presented both in terms of
patient-level classification metrics with an explicit and
motivated definition of true positive and negative, false
positive and negative; and in terms of the trade-off be-
tween anomaly-level sensitivity and individual false pos-
itives rate, such as the free-recall ROC (FROC) curve? Is
the matching criterion, such as intersection-over-union
threshold, clearly defined?
& For segmentation algorithms: Are both overall voxel-level
metrics such as Jaccard or Dice coefficients and absolute
volume differences provided? Are instance-level metrics
such as per-lesion accuracy metrics provided?
Have the developers identified and accounted for
potential sources of bias in their algorithm?
AI algorithms can learn human biases (e.g., towards race,
gender, or socioeconomic status) from their training data or
in their application. Awareness of the potential for bias is
critical. Thus, vendors should be ready to discuss how their
training data were collected, how the model was trained, and
how the evaluation process ensures that outputs are as unbi-
ased as possible [28]. Vendors should also be asked to provide
evidence of hidden stratification or sub-stratification analyses
to check for unknown biases affecting data sub-groups.
Is the algorithm fixed or adapting as new data comes
in?
AI algorithms typically are trained with a fixed dataset
before being deployed. A more recent trend is to allow
AI algorithms to continuously adapt by including more
data, hereby improving performance and adapting to slow
changes in imaging equipment and population. Relevant
questions include:
& Does the system adapt to your local data over time or via
updates?
& Is feedback obtained from the users (such as pointing out
erroneous detections) incorporated?
& If the algorithm undergoes continuous improvement, is
that covered by the regulatory approval? Currently, no
adaptive AI systems are regulatory approved, though this
may change as the technology progresses.
& If performance is increased in future updates, the algo-
rithm is changed. How are results obtained with the prior
versions handled? Will they still be valid and can one still
compare them to the results obtained with the new version
of the algorithm?
Usability and integration
How can the application be integrated into your
clinical workflow?
Ideally, the data processing should take place in the back-
ground and be fast enough for the results to be available when
the radiologist is reading and reporting examinations.
Questions to consider include:
& Is manual interaction needed, or is the processing per-
formed automatically in the background?
& How fast is the processing cycle from data acquisition to
the result?
& How can the processing status of a specific dataset be
checked?
The application to be used by radiologists should aim
to be fully integrated with the picture archiving and
communication system (PACS) and accessible with a
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minimum of mouse clicks—this is key for clinical us-
ability. Are the AI tool and its results readily accessible
in the working environment, and with a user-friendly
interface? For SaMDs, it is important to check whether
the vendor has undertaken validation according to the
International Organization for Standardization (ISO)
standards; ISO 62633 relates to the usability and safety
of medical devices [29]. It is advisable to involve the IT
department and PACS specialists early in the evaluation
process.
Finally, questions to consider in terms of how the user can
manage the software include:
& Is there integration of identity management with the hos-
pital system?
& Are there different roles/users defined in the product?
& Who can assign new users and/or roles? How much work
does this represent?
& If interaction is needed, are all actions trackable?
How exactly does the application impact the
workflow?
AI applications may be able to improve workflow. For
example, triage and prioritization of the report list based
on automatic identification of abnormalities can prioritize
important cases. The application output such as qualita-
tive or quantitative data could be used to automatically
populate structured reports; impact on reading and
reporting time should be quantified. However, it is impor-
tant to identify all roles involved in the new workflow,
including non-physicians such as technicians. Indeed,
some resources might have to be reallocated for certain
tasks. The reporting structure might also have to be
changed with the use of the AI solution. These factors
need to be taken into account in the decision process.
What are the requirements in terms of information
technology (IT) infrastructure?
For on-premise deployment, some AI applications may re-
quire specialized computer hardware such as graphics pro-
cessing units (GPU), which are not present in all computers.
Not all GPUs are equivalent, so requirements in terms of GPU
computation power (e.g., “compute unified device architec-
ture (CUDA) compute level”) and memory (e.g., “11 GB or
more”) should be made clear. Some models cost significantly
more than a typical desktop computer. Likewise, central pro-
cessing unit (CPU) specifications, memory, disk storage, and
energy requirements must be made clear. Depending on the
above, the solution may require significant additional ex-
penses if new hardware has to be acquired.
For cloud solutions, requirements are usually lighter.
Nevertheless, network security and network performance is-
sues need to be discussed. It is highly advisable to consult the
IT department early.
Interoperability—how can the data be exported for
research and other purposes?
The output format and the accessibility of the results may
impact interoperability. For applications that are not fully in-
tegrated in the PACS, it is important to consider the following
questions:
& How can the data be exported for research purposes? Are
there accessible application programming interfaces (API)
such as a DICOMweb interface?
& Is the output in a standards-compliant format such as
Digital Imaging and Communications in Medicine
(DICOM) structured report (SR) following SR template
identifier (TID) 1500?
& Are standard export formats (e.g., simple comma-
separated values (CSV) format) supported?
& Are the results saved, or must the computation be per-
formed anew every time?
Of note, some initiatives to improve interoperability of AI
solutions with existing standards-based healthcare systems
exist [30].
Will the data be accessible to non-radiologists (refer-
ring physicians, patients)?
If applicable, consider whether the data are presented in a form
that is suitable to be transferred to patients, or understandable
by referring physicians.
Are the AI model’s results interpretable?
Depending on how it is to be used, it may be critical for the AI
system to be able to explain its reasoning or to provide a
means for physicians to interpret its output. One popular ap-
proach is a visualization, where a heat map of the importance
of specific image regions is overlaid on top of the initial image
[31].
Regulatory and legal aspects
Regulatory and legal requirements vary around the world.
Nevertheless, due to their characteristics, AI applications used
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in radiology must comply with two main regulatory and legal
frameworks: the medical device and the personal data protec-
tion regulations.
Does the AI application comply with the local medical
device regulations?
The manufacturer must define a use case for its application
and specify whether it should be used as a medical device, and
under which risk class. Medical devices are classified into risk
classes from I to III; the riskier the medical device, the more
regulatory controls are applied. Implementation processes
vary from country to country and the first question that must
be addressed is whether the AI application has been cleared/
approved in the target country [32].
For Europe, is the AI application CE marked?
For class I medical devices, the manufacturer can perform
self-certification and certify that its device is compliant with
regulations, without the involvement of an independent body.
For higher risk classes, which represent the vast majority of
AI-based SaMDs, the manufacturer must appoint a notified
body that will review both the technical documentation of
the medical device and the processes in place in the company
before issuing a CE certificate.
In Europe, the regulatory framework to put a device on
the market is currently changing from the Directive to the
Medical Device Regulation (MDR) [33, 34]. The applica-
tion of the MDR will enter into application on May 26,
2021. Medical devices that comply with the Directive are
given a transition period of up to four years during which
they can remain on the market. However, this is only
applicable when no substantial modifications are planned
on the medical device. Otherwise, the manufacturer would
have to conform to the MDR. An additional question
would then be is the manufacturer already planning on
transitioning to the MDR?
From January 1, 2021, the United Kingdom (UK) will re-
quire international importers to register separately with the
UK Medicines and Healthcare products Regulatory Agency
(MHRA), while a transition from CEmarking to UKCA takes
place until the 30th of June 2023 [35].
For the US, is the AI application FDA-cleared
or FDA-approved?
To be lawfully put on the US market, a medical device must
be reviewed by the FDA [36, 37], using either the De Novo
pathway, for innovative medical devices that have no equiva-
lent (FDA approval) [38]; or the 510(k) pathway, for medical
devices that have an equivalent predicate already on the US
market (FDA clearance) [39].
FDA approval/clearance is often considered a quality
stamp because the FDA remains one of the most demanding
regulators in the world. Thus, manufacturers might want to
purposely reduce the scope of the AI application for the
FDA submission file. Particular attention must be paid to the
scope of an FDA-approved/FDA-cleared device, and whether
the non-US version of the device is different from the US
version, and how. Additionnally, the FDA is currently build-
ing a new regulatory framework for the evlaluation of AI-
based SaMDs [40].
Other medical device regulations
For other geographical areas, there are three scenarios for
regulatory approval.
First, the target country recognizes FDA clearance/
approval and CE marking as equivalent to its level of
requirements: in this case, the manufacturer faces less
challenges but still must register with the local
authorities.
Second, the target country does not recognize either FDA
approval/clearance or CE marking and has its own regulation.
It is the case for example in Japan where the manufacturer
must submit an application to the Pharmaceutical and
Medical Devices Agency (PMDA) or in China where the
manufacturer must submit an application to the National
Medical Products Administration (NMPA).
Third, several countries including the USA, Australia,
Brazil, Canada, and Japan accept the Medical Device Single
Audit Program (MDSAP) certification which is well-aligned
with the MDR [41].
Does the AI application comply with the data
protection regulations?
AI systems handle sensitive health-related data that fall under
regulations such as those in place for medical devices. For
example, the General Data Protection Regulation (GDPR) is
in place in Europe while the Health Insurance Portability and
Accountability Act (HIPAA) applies to the US [34, 42].
Compliance with these regulations is most of the time a
two-sided process with contractual arrangements between
users and the manufacturer and security measures that need
to be in place. The following questions can help assess the
readiness of the manufacturer:
& What are the contractual guarantees given by the manu-
facturer? Are there specific clauses in the contract related
to the protection of data?
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& Does the manufacturer have a reference person for data
protection issues?
& Does the processing of data occur on premise or remotely?
Is the manufacturer or the subcontractor hosting the pro-
cessing compliant with information security standards
ISO 27001/27017/27018?
& Is the data pseudonymized, and if yes, where are the map-
ping tables stored?
Financial and support services considerations
AI applications are complicated pieces of software that rely on
several other software and hardware components. Thus, in
addition to pricing, questions about maintenance, training,
and support need to be discussed prior to committing to a
purchase. This is in addition to the internal hospital IT costs
mentioned in the “How exactly does the application impact
the workflow” section.
What is the licensing model?
With the rise of software-as-a-service (SaaS) and subscription
models, it is not always trivial to compute total cost of own-
ership. The following questions must be clarified:
What is the business model: is it a one-time fee, a subscrip-
tion, or a pay-per-use model? Are there discounts based on
processed imaging volume? If it is a subscription plan, what
are the cancellation procedure/delays?
& Does the manufacturer offer a trial period? Is it possible to
proceed to a real-life evaluation of the product on the
hospital’s own data before purchase?
& What are the exact costs now, and in the future (install
costs, yearly software license, maintenance fees, costs of
potential future updates, internal efforts, etc.)?
& How does the solution scale to more users, or more
DICOM modalities (devices)? Would there be additional
costs?
& Is the AI system offered through an “App store” portal
from an established EHR, dictation, or PACS vendor, or
AI marketplace? If so, will the purchase of that application
simplify your access to other applications in the future (by
leveraging the same computing architecture and/or AI user
interface)?
How are user training and follow-up handled?
Like other IT products, AI systems need some time to get used
to and offer various degrees of user-friendliness. To ensure
radiologists will use the system efficiently, training and sup-
port are necessary. The following points should be discussed:
& Does the purchase of the product include training ses-
sions? Who should participate and how much time is re-
quired per function?
& Can additional training sessions be arranged for new
users? How much would that cost?
& If a question comes up, is there a way to contact the vendor
and a guaranteed reaction time?
How is the maintenance of the product ensured?
Because AI systems live within a constantly evolving clinical
ecosystem, questions around the maintenance of the product
are important to consider. A few essential questions should
clarify how that will happen:
& Will there be regular maintenance?
& If the product is down, would it still be possible to proceed
with reading the relevant images by other means? What is
the procedure for repair? What would be the delay? Who
would have to cover the costs?
& What is the guaranteed uptime of the servers the software
runs on?
How will potential malfunctions or erroneous results
be handled?
NoAI application is perfect. With exposure to real-life, highly
variable clinical datasets, errors can happen. The following
points have to be clarified before purchase:
& How will malfunctions be addressed? If severe, is there a
guarantee that the problem will be fixed?
& What is the pathway to file a potential malfunction? Is
there an automatic monitoring in place or do the users
have to report malfunctions?
& What are the adverse event reporting pathways?
& How is post market surveillance and post market clinical
follow-up to be conducted?
Conclusion
This work aims to provide a list of practical points to address
when considering whether to invest in an AI solution in med-
ical imaging. Although some assessment criteria presented
here may not apply to every situation, we hope to have devel-
oped a framework that will allow all stakeholders to conduct
Eur Radiol
relevant discussions with manufacturers and reach an in-
formed decision.
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